Advances in the treatment of autoimmune nodopathy: based on treatment strategies of CIDP - PubMed
4 hours ago
- #autoimmune nodopathy
- #CIDP treatment
- #rituximab
- Autoimmune nodopathy (AN) is now recognized as a distinct condition from CIDP, classified by 2021 EAN/PNS guidelines, involving autoantibodies against proteins like CNTN1 and NF155.
- Standard first-line treatments for CIDP include corticosteroids, IVIG, and plasma exchange, with immunosuppressants as alternatives if needed; new strategies like efgartigimod are emerging.
- Treatment for AN differs significantly, with rituximab as the preferred option, corticosteroids effective in some cases, plasma exchange for severe cases, and IVIG largely ineffective.
- Due to AN's low incidence and limited evidence, treatment strategies require validation through large-scale clinical trials.
- This review highlights advancements in CIDP treatment and focuses on the unique therapeutic approaches for autoimmune nodopathy.